Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
Atug
Ozlen
O
Akin
Hakan
H
Yilmaz
Yusuf
Y
Sari
Murat
M
Tozun
Nurdan
N
D000998:Antiviral Agents / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D004359:Drug Therapy, Combination; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a